Overview
- Stratus (XFG), a recombinant of Omicron subvariants F.7 and LP.8.1.2, made up about 14% of U.S. COVID-19 cases by late June and 22.7% of global infections
- In a late June update, the World Health Organization added XFG to its monitoring list and judged its public health risk as low while affirming that existing vaccines remain effective
- Laboratory data indicate Stratus carries mutations that may aid immune evasion but do not appear to boost transmissibility or cause more severe disease
- Clinicians in Connecticut report an uptick in COVID-19 admissions linked to Stratus, with patients responding to standard antiviral treatments including Paxlovid
- Health authorities emphasize the need for ongoing genomic surveillance and higher booster uptake to sustain protection and prepare for further viral evolution